Ameritas Investment Partners’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $116K | Buy |
9,086
+791
| +10% | +$10.1K | ﹤0.01% | 1599 |
|
|
2025
Q4 | $74.6K | Hold |
8,295
| – | – | ﹤0.01% | 1871 |
|
|
2025
Q3 | $143K | Sell |
8,295
-1,465
| -15% | -$18K | ﹤0.01% | 1454 |
|
|
2025
Q2 | $91.5K | Hold |
9,760
| – | – | ﹤0.01% | 1815 |
|
|
2025
Q1 | $69.4K | Hold |
9,760
| – | – | ﹤0.01% | 1925 |
|
|
2024
Q4 | $114K | Hold |
9,760
| – | – | ﹤0.01% | 1686 |
|
|
2024
Q3 | $201K | Buy |
9,760
+627
| +7% | +$14.5K | 0.01% | 1322 |
|
|
2024
Q2 | $204K | Hold |
9,133
| – | – | 0.01% | 1249 |
|
|
2024
Q1 | $251K | Hold |
9,133
| – | – | 0.01% | 1137 |
|
|
2023
Q4 | $278K | Buy |
9,133
+367
| +4% | +$10.5K | 0.01% | 1072 |
|
|
2023
Q3 | $277K | Buy |
8,766
+1,480
| +20% | +$57.4K | 0.01% | 991 |
|
|
2023
Q2 | $297K | Buy |
7,286
+755
| +12% | +$30.6K | 0.01% | 930 |
|
|
2023
Q1 | $243K | Sell |
6,531
-270
| -4% | -$10.6K | 0.01% | 984 |
|
|
2022
Q4 | $244K | Buy |
6,801
+889
| +15% | +$42.3K | 0.01% | 1021 |
|
|
2022
Q3 | $330K | Buy |
5,912
+256
| +5% | +$15.9K | 0.01% | 860 |
|
|
2022
Q2 | $292K | Buy |
5,656
+276
| +5% | +$14K | 0.01% | 902 |
|
|
2022
Q1 | $391K | Hold |
5,380
| – | – | 0.01% | 868 |
|
|
2021
Q4 | $636K | Hold |
5,380
| – | – | 0.02% | 752 |
|
|
2021
Q3 | $722K | Buy |
5,380
+371
| +7% | +$56.2K | 0.03% | 703 |
|
|
2021
Q2 | $811K | Buy |
5,009
+547
| +12% | +$42.6K | 0.03% | 681 |
|
|
2021
Q1 | $358K | Buy |
4,462
+192
| +4% | +$12.9K | 0.01% | 887 |
|
|
2020
Q4 | $232K | Hold |
4,270
| – | – | 0.01% | 1057 |
|
|
2020
Q3 | $85K | Buy |
4,270
+398
| +10% | +$8.3K | ﹤0.01% | 1531 |
|
|
2020
Q2 | $81K | Buy |
3,872
+826
| +27% | +$14K | ﹤0.01% | 1542 |
|
|
2020
Q1 | $37K | Hold |
3,046
| – | – | ﹤0.01% | 1834 |
|
|
2019
Q4 | $45K | Hold |
3,046
| – | – | ﹤0.01% | 1984 |
|
|
2019
Q3 | $41K | Buy |
3,046
+465
| +18% | +$7.41K | ﹤0.01% | 2002 |
|
|
2019
Q2 | $42K | Hold |
2,581
| – | – | ﹤0.01% | 2012 |
|
|
2019
Q1 | $44K | Hold |
2,581
| – | – | ﹤0.01% | 1955 |
|
|
2018
Q4 | $35K | Hold |
2,581
| – | – | ﹤0.01% | 2010 |
|
|
2018
Q3 | $74K | Hold |
2,581
| – | – | ﹤0.01% | 1744 |
|
|
2018
Q2 | $71K | Buy |
2,581
+1,336
| +107% | +$32.4K | ﹤0.01% | 1775 |
|
|
2018
Q1 | $26K | Hold |
1,245
| – | – | ﹤0.01% | 2288 |
|
|
2017
Q4 | $24K | Hold |
1,245
| – | – | ﹤0.01% | 2355 |
|
|
2017
Q3 | $26K | Hold |
1,245
| – | – | ﹤0.01% | 2282 |
|
|
2017
Q2 | $20K | Buy |
1,245
+701
| +129% | +$9.79K | ﹤0.01% | 2452 |
|
|
2017
Q1 | $8K | Buy |
+544
| New | +$7.3K | ﹤0.01% | 2760 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
Ameritas Investment Partners's NTLA Position: Q1 2026 in Review
Ameritas Investment Partners increased its Intellia Therapeutics (NTLA) stake by 9.5% in Q1 2026, buying an estimated $10.1K and bringing the position to 9,086 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #1599.
Ameritas Investment Partners first reported a position in NTLA in Q1 2017 and has held it in 37 quarters since. The position peaked at $811K in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.
- Ameritas Investment Partners held 9,086 shares of Intellia Therapeutics worth $116K as of Q1 2026.
- Ameritas Investment Partners bought 791 Intellia Therapeutics shares in Q1 2026, an estimated $10.1K.
- Intellia Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1599 holding.
- Ameritas Investment Partners first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 37 quarters since.
- Ameritas Investment Partners's Intellia Therapeutics position peaked at $811K in Q2 2021.
- 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.
Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.